Tafolecimab, CAS 2225109-03-3

Product Description: Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia[1].

Applications: Neuroscience-Neuromodulation

Formula: N/A

References: [1]Y Cui, et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects .European Heart Journal, Volume 41, Issue Supplement_2, November 2020.

CAS Number: 2225109-03-3

Molecular Weight: N/A

Compound Purity: 95.04

Research Area: Cardiovascular Disease

Solubility: 10 mM in DMSO

Target: PCSK9

• Artikelnummer: MEXHY-P99552-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99552-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated